

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Brilliant Violet 785(TM) anti-mouse CD3

RRID:AB_2562554

Type: Antibody

Proper Citation

BioLegend Cat# 100232, RRID:AB_2562554

Antibody Information

URL: http://antibodyregistry.org/AB_2562554

Proper Citation: BioLegend Cat# 100232, RRID:AB_2562554

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2562554

Vendor: BioLegend

Catalog Number: 100232

Alternative Catalog Numbers: 100231

Record Creation Time: 20250820T043455+0000

Record Last Update: 20250820T192152+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kimura N, et al. (2025) Regulatory T cell stability determines the efficiency of bile duct regeneration during cholangitis. Cell reports, 44(11), 116557.

Castañó D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell, 188(26), 7461.

Stockmann AP, et al. (2025) DF6215, an α -optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. Cell reports. Medicine, 102518.

Katkeviciute E, et al. (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. Cell reports, 44(3), 115357.

Nagata M, et al. (2024) A shorter splicing isoform antagonizes ZBP1 to modulate cell death and inflammatory responses. The EMBO journal, 43(21), 5037.

Hulin-Curtis S, et al. (2024) A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell reports, 43(6), 114259.

Brook B, et al. (2024) The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo. iScience, 27(11), 111055.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer cell, 42(7), 1286.

Simon M, et al. (2024) Single-cell chromatin accessibility and transposable element landscapes reveal shared features of tissue-residing immune cells. Immunity, 57(8), 1975.

Imai T, et al. (2024) The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. Immunity, 57(7), 1497.

Barreiro A, et al. (2023) Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. iScience, 26(3), 106126.

Liu H, et al. (2022) Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates Fc γ R-independent GITR agonism and antitumor activity. *Cell reports. Medicine*, 3(6), 100660.

Christian DA, et al. (2022) cDC1 coordinate innate and adaptive responses in the omentum required for T cell priming and memory. *Science immunology*, 7(75), eabq7432.

Yousif AS, et al. (2021) The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells. *Immunity*, 54(2), 235.

Glassman CR, et al. (2021) Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. *eLife*, 10.

Montalban-Arques A, et al. (2021) Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. *Cell host & microbe*, 29(10), 1573.

Shreeve N, et al. (2021) The CD94/NKG2A inhibitory receptor educates uterine NK cells to optimize pregnancy outcomes in humans and mice. *Immunity*, 54(6), 1231.

Goh W, et al. (2020) Hhex Directly Represses BIM-Dependent Apoptosis to Promote NK Cell Development and Maintenance. *Cell reports*, 33(3), 108285.

Sangesland M, et al. (2020) A Single Human VH-gene Allows for a Broad-Spectrum Antibody Response Targeting Bacterial Lipopolysaccharides in the Blood. *Cell reports*, 32(8), 108065.

Pai CS, et al. (2019) Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. *Immunity*, 50(2), 477.